(2)
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance
ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued United States Patent 10888898 (the 898 patent) entitled Shielded Ultrasound Transducer and Imaging System Employing the Same from the United States Patent and Trademark Office. This is the 13
th U.S. patent issued to ENDRA for its TAEUS
® technology. ENDRA s goal is to develop applications for our proprietary TAEUS
® technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued 898 patent provides more robust intellectual property (IP) protection for our TAEUS
ENDRA Life Sciences Granted 13th U S Patent for its TAEUS(R) Platform Technology newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology,
Ophthalmology
® gene therapy in
ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper , published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset”, is the second peer-reviewed article based on Phase III clinical trial data to document comparable bilateral improvement in visual outcomes from a unilateral injection of a gene therapy.
Known as iSTAT, the test requires drawing a blood sample from a patient and looking for two blood biomarkers, and can deliver results within 15 minutes and 95% accuracy.
Pulmonologist, sleep medicine specialist joins PVH
Kurdi
POINT PLEASANT, W.Va. Pleasant Valley Hospital (PVH) announces pulmonologist and sleep medicine specialist Mostafa Kurdi, M.D., FCCP, has joined its medical staff.
According to a news release from PVH, “Dr. Kurdi is welcoming patients to his outpatient practice.”
The release went on to state, “Dr. Kurdi is a highly specialized, board-certified, and fellowship-trained pulmonologist who has managed all aspects of pulmonary and sleep medicine for more than 17 years. He earned four board certifications with the American Board of Internal Medicine including Internal Medicine, Sleep Medicine, Pulmonology, and Critical Care. Dr. Kurdi holds certifications in advanced cardiac life support and basic life support.